Osaka-based Maruho Co., Ltd has acquired Cutanea Life Sciences Inc., a U.S. private dermatology development company based in Pennsylvania. Maruho hopes to build up its dermatology business in the U.S. through CLS’s network and development capability. Maruho also gains access to CLS’s product pipeline and know-how in new drug discovery in the U.S. market. Since establishing its first U.S. local branch last year, Maruho has accelerated expansion in overseas markets. (Click here for more – Japanese language
Japanese Specialty Pharma Maruho Acquires Cutanea Of U.S.
Osaka-based Maruho Co., Ltd has acquired Cutanea Life Sciences Inc., a U.S. private dermatology development company based in Pennsylvania.
More from Japan
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.
• By
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
More from Focus On Asia
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?